## EGFR-IN-30

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-144044 2726463-68-7 C <sub>28</sub> H <sub>33</sub> BrN <sub>7</sub> O <sub>2</sub> P 610.49 EGFR JAK/STAT Signaling; Protein Tyrosine Kinase/RTK Please store the product under the recommended conditions in the Certificate of Analysis.	$ \begin{array}{c} P^{\geq 0} \\ H \\ Br \end{array} \\ N \\$
---	---	---

BIOLOGICAL ACTIV			
BIOLOGICALACITITI			
Description	EGFR-IN-30 is a potent EGFR inhibitor with IC <sub>50</sub> s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research <sup>[1]</sup> .		
IC <sub>50</sub> & Target	EGFR (WT) 1-10 nM (IC <sub>50</sub> )	EGFR (L858R/T790M/C797S) <1 nM (IC <sub>50</sub> )	
In Vitro	EGFR-IN-30 (compound 27) inhibits A431 cell (IC <sub>50</sub> =100-1000 nM),Ba/F3_L858R/T790M/C797S cell (IC <sub>50</sub> <10 nM), Ba/F3_Del19/T790M/C797S cell (IC <sub>50</sub> <10 nM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

## REFERENCES

[1]. Shansong Zheng, et al. Tricyclic compounds as EGFR inhibitors. WO2021208918A1.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

